CDK12 Defines a MED1-Dependent Transcriptional Addiction Axis in Estrogen Receptor–Positive Breast Cancer
Abstract
Background: Cyclin-dependent kinase 12 (CDK12) is frequently altered in breast cancer, classically as a passenger within the ERBB2 amplicon. However, CDK12 also regulates RNA polymerase II (RNAPII) elongation and enhancer-driven transcription, suggesting a broader role in estrogen receptor (ER)–dependent gene regulation.
Methods: We integrated mechanistic findings from prior experimental studies with systems-level validation using The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) cohort (n = 1,227). STAR RNA-seq expression (log₂[FPKM-UQ]) was analyzed for CDK12, MED1, ERBB2, and ESR1. Correlation analyses, subtype-resolved comparisons (PAM50), and dual-axis modeling were performed to distinguish genomic dosage effects from transcriptional co-activation.
Results: CDK12 and MED1 exhibit near-perfect transcriptional coupling across TCGA-BRCA tumors (Pearson r = 0.936, p < 2.2 × 10⁻¹⁶), far exceeding the correlation between CDK12 and ERBB2 (r = 0.587). PAM50 subtype analysis demonstrates that ERBB2 expression is restricted to the HER2-enriched subtype, whereas CDK12–MED1 coupling persists across luminal tumors independent of ERBB2 amplification. These findings define a transcriptional addiction axis in ER-positive disease that is mechanistically distinct from ERBB2-driven genomic dosage.
Conclusions: CDK12 operates in breast cancer through a dual regulatory architecture: (i) a genomic dosage axis driven by ERBB2 co-amplification and (ii) a MED1-dependent transcriptional co-activation axis that sustains ER enhancer output. This transcriptional addiction state provides a mechanistic rationale for therapeutic targeting of CDK12 in ER-positive breast cancer.
References
Dehghani A. The Immunoregulatory Roles of ERα in Breast Cancer: Mechanisms, Crosstalk, and Therapeutic Insights. J Cancer Prev. 2026;31(1):1-10.
Ottaviani D, Ola M, Allotta A, Maati Chaibi Y, Hickey S, Jagust P, et al. Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. JNCI: Journal of the National Cancer Institute. 2025.
Lehrer S. Re: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. JNCI: Journal of the National Cancer Institute. 2026.
Varešlija D, Ottaviani D, Young L. Response to Lehrer. JNCI: Journal of the National Cancer Institute. 2026.
Liang S, Hu L, Wu Z, Chen Z, Liu S, Xu X, et al. CDK12: A Potent Target and Biomarker for Human Cancer Therapy. Cells. 2020;9(6).
Choi HJ, Jin S, Cho H, Won HY, An HW, Jeong GY, et al. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 2019;20(10):e48058.
Salgado R, Kok M. Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity. Clin Cancer Res. 2026;32(11):2133-5.
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016;2:15023-.
Chang Y, Wang X, Yang J, Tien JC-Y, Mannan R, Cruz G, et al. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell Reports Medicine. 2024;5(10).
Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol. 2021;17(6):675-83.
Authors
Copyright (c) 2026 Steven Lehrer, Peter Rheinstein
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.